celecoxib has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 5 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was tested in combination with imatinib, demonstrating that celecoxib could strengthen the cytotoxicity of imatinib in imatinib-resistant CML cells." | 1.43 | Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. ( Deng, XB; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Liu, SS; Long, ZJ; Lu, Y; Zou, Y, 2016) |
| "Treatment with celecoxib also restored GSK3β function and led to down-regulation of β-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib." | 1.43 | Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. ( Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P, 2016) |
| " Therefore, we examined the effect of rapamycin combined with celecoxib on K562 cells in vitro." | 1.40 | Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway. ( Hao, H; Li, J; Li, R; Luo, J; Xue, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Xue, L | 1 |
| Hao, H | 1 |
| Li, R | 1 |
| Luo, J | 1 |
| Lu, Y | 1 |
| Liu, LL | 1 |
| Liu, SS | 1 |
| Fang, ZG | 1 |
| Zou, Y | 1 |
| Deng, XB | 1 |
| Long, ZJ | 1 |
| Liu, Q | 1 |
| Lin, DJ | 1 |
| Riva, B | 1 |
| De Dominici, M | 1 |
| Gnemmi, I | 1 |
| Mariani, SA | 1 |
| Minassi, A | 1 |
| Minieri, V | 1 |
| Salomoni, P | 1 |
| Canonico, PL | 1 |
| Genazzani, AA | 1 |
| Calabretta, B | 1 |
| Condorelli, F | 1 |
| Subhashini, J | 1 |
| Mahipal, SV | 1 |
| Reddanna, P | 1 |
| Zhang, GS | 1 |
| Liu, DS | 1 |
| Dai, CW | 1 |
| Li, RJ | 1 |
5 other studies available for celecoxib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle Checkpoints; Cell L | 2014 |
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Topics: Adult; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G1 Phas | 2016 |
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; DNA Damage; Down-Regulation; Fo | 2005 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone M | 2006 |